Crism Therapeutics Corporation

CRTX · AIM · Health Care · mcap £7.4m · 9.0p

Beta Briefing, track record and bull & bear case are not ready for Crism Therapeutics Corporation yet.

We follow 817 UK small caps and every one of their announcements – often hundreds per company. 38 companies are already wired into a briefing: browse them.

All announcements Monitoring checked today, 10:35

All · 32 Key · 23

Date	Type	Announcement	Day
02 Oct 26	Routine	Notice of AGM
21 Sep 26	Results	Half-year Results (“CRISM”, “CRISM Therapeutics”, the “Company” or the “Group”)	+0.0%
17 Sep 26	Board change	Appointment of Non-executive Chair CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce the appointment of Dr Charles Spicer as	−9.3%
20 Aug 26		Commencement of Patient Recruitment 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+0.0%
13 Aug 26		Clinical Trial Update 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+7.5%
29 Jul 26	Holding	Holding(s) in Company
27 Jul 26		Result of Shareholder Analysis CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third	+0.0%
02 Jul 26	Holding	Holding(s) in Company
30 Jun 26	Routine	Grant of Options
26 Jun 26	Results	Final Results 'Regulatory milestones achieved and well-funded to advance Phase 2 Clinical Trial'	+0.0%
25 Jun 26		Phase 2 Clinical Trial Progress Update 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	−2.4%
22 Jun 26	Holding	Holding(s) in Company
16 Jun 26	Holding	Holding(s) in Company
15 Jun 26	Routine	Result of General Meeting
04 Jun 26		Significant Grant Award 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+4.5%
01 Jun 26		Grant Award 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+2.3%
28 May 26	Fundraise	Result of Retail Offer This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Cor	+0.0%
27 May 26	Routine	Notice of General Meeting
26 May 26	Fundraise	Retail Offer to raise up to £100,000 CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, is pleased to announce a retail offer via BookBuild (the "Retai	−8.7%
26 May 26	Fundraise	Placing of £2.5 million This Announcement does not constitute a prospectus or offering memorandum or an offer in respect of any securities and is not intended to provide the basis for any investment decision in respect of CRISM Therapeutics Cor	−8.7%
21 Apr 26		Positive Preclinical Data for Docetaxel ChemoSeed 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+10.6%
02 Apr 26	Board change	Directorate Change 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	−6.4%
25 Mar 26		Phase 2 Clinical Trial Progress Update 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	−11.8%
17 Mar 26		Awarding of Orphan Drug Designation by the FDA 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+20.8%
20 Jan 26		Japanese Patent Grant CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that it has been granted a patent (7800909) by the Ja	+2.5%
09 Jan 26	Results	Results of Shareholder Analysis CRISM Therapeutics Corporation (AIM: CRTX), a UK clinical-stage drug delivery company focused on the localised and sustained delivery of chemotherapy drugs, announces that following the completion of an independent third	+0.0%
15 Dec 25	Fundraise	Result of Retail Offer 596/2014, AS INCORPORATED INTO UK LAW BY THE EUROPEAN UNION (WITHDRAWAL) ACT 2018 ("UK MAR").	+0.0%
10 Dec 25	Fundraise	Retail Offer CRISM Therapeutics Corporation (the "Company") is pleased to announce a retail offer via BookBuild (the "Retail Offer") of new ordinary shares ("Ordinary Shares") of nil par value each in the capital of the Company (the	−20.5%
10 Dec 25	Fundraise	Placing of £1,000,000 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	−20.5%
27 Nov 25	Holding	Holding(s) in Company
30 Oct 25		US Orphan Drug Designation Application Submission of Orphan Drug Designation Application to the FDA for Irinotecan-ChemoSeed™ in Glioblastoma	+0.0%
14 Oct 25		Positive Preclinical Data in Prostate Cancer 596/2014, as incorporated into UK law by the European Union (Withdrawal) Act 2018.	+0.0%

Company filings. Not investment advice.